Cyclopamine, acting on the PTCH-SMO complex, has demonstrated efficacy in reducing glioma, glioblastoma, and MB growth in mouse models and inhibiting human MB cell lines in vitro [132–134]. Here, PTCH1 is linked to central nervous system cancer.